Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based immunotherapies and vaccines for infectious diseases, cancer, and other serious health conditions. Established in 2001, the company advances its research through proprietary DNA delivery technology and seeks to create innovative solutions to address unmet medical needs worldwide.
Company News
Arch Therapeutics is developing innovative self-assembling barrier technologies for interventional wound care, focusing on advanced hemostasis and sealant solutions across multiple medical applications.
A comprehensive market research report highlighting the cancer vaccine landscape in 2024/25, featuring 76 new cancer vaccines, over 300 drug events, and 1,412 programs leveraging advanced genomics, AI, and mRNA technologies.
Both biotechs have been struggling for a while, but there might be some hope for them.
Stephens initiated coverage on INOVIO Pharmaceuticals Inc (NASDAQ:INO), noting the company’s diversified clinical pipeline of therapeutic and vaccine candidates, which the company is looking to advance eight additional clinical-stage candidates. The analyst writes that the FDA considered lead program INO-3107 Phase 1/2 clinical trials suf...
INO earnings call for the period ending March 31, 2024.
